In 808 women with high risk early triple negative breast cancer, adding carboplatin to adjuvant anthracycline/taxane chemotherapy gave estimated 3-year disease-free survival of 92.3% vs 85.8% (HR 0.64); benefit was early. Grade 3-4 adverse events: 66.7% vs 55.0%.
RCTn = 808
Liu et al. Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial